PDRN, bakuchiol, and GHK-Cu: separating real anti-aging data from TikTok glow claims

What's this video probably claiming?

Based on the caption and product lineup, @songofskin is framing topical PDRN (polydeoxyribonucleotide), bakuchiol, and likely GHK-Cu copper peptides as a prevention-first approach to early aging signs like fine lines, texture, and dullness. The framing, "your skin asking for collagen support and cell repair," is classic K-beauty content: soften the clinical language just enough to sound informative without triggering regulatory flags. The Rejuran Turnover Ampoule is marketed around PDRN, a salmon-derived nucleotide compound with wound-healing origins. Bakuchiol is positioned as a retinol alternative for sensitive skin. The hashtag #glassskinroutine signals the video is selling an aesthetic outcome, not just a product. Given the category this video falls into, it is likely also gesturing at the broader peptide-for-skin-repair conversation, where ingredients like GHK-Cu get bundled with PDRN as part of a unified "cellular repair" narrative, even though their mechanisms and evidence bases are quite different.

What does the science actually show?

PDRN has a more credible evidence base than most TikTok ingredients, though most of the good data comes from injected formulations, not topicals. A 2014 study by Veronesi et al. in the Journal of Biological Regulators and Homeostatic Agents showed PDRN accelerated wound healing via adenosine A2A receptor activation. A 2021 randomized trial by Arani et al. in Dermatologic Surgery found intradermal PDRN injections improved photoaged skin texture scores compared to saline controls. Topical PDRN absorption through intact skin is a different question, and the data there is thinner. Bakuchiol is better studied topically: Dhaliwal et al. (2019, British Journal of Dermatology) ran a 12-week split-face RCT showing 0.5% bakuchiol twice daily produced comparable reductions in fine lines and pigmentation to 0.5% retinol, with fewer side effects. GHK-Cu has in vitro collagen synthesis data (Pickart and Margolina, 2018, Cosmetics) but controlled human trials showing meaningful cosmetic endpoints are limited. The peptide works, probably, but the effect sizes in real-world topical use are modest.

Where does the social media noise diverge from clinical reality?

The biggest gap here is delivery versus mechanism. A creator can accurately describe what PDRN or GHK-Cu does in a lab context and still be misleading about what a serum does to your face. Topical penetration of large peptide molecules through the stratum corneum is genuinely hard. PDRN molecules range from 50 to 1500 kDa depending on processing; most effective transdermal cutoffs are under 500 Da. This is not a fringe concern. A 2020 review by Errante et al. in Biomedical Dermatology flagged that cosmetic PDRN products often lack standardized concentration or molecular weight data, making efficacy comparisons between clinical trials and consumer serums nearly impossible. The "barrier repair" claim for topical PDRN is plausible but not well-proven for over-the-counter concentrations. Meanwhile, calling early fine lines and dullness a sign your skin is "asking for collagen support" is teleological language that sounds scientific but describes a marketing angle, not a diagnostic framework. Prevention messaging is not wrong, but it tends to compress a decade of gradual photoprotection into a product-purchase moment.

What should you actually know?

If you are genuinely interested in evidence-based topical anti-aging, the ingredient hierarchy still looks like this: broad-spectrum SPF daily (strongest preventive evidence by far), topical retinoids, and then a long drop-off to everything else. Bakuchiol sits somewhere in that third tier with reasonable supporting data for people who cannot tolerate retinol. Topical GHK-Cu is worth watching but not worth anchoring a routine around given current evidence. Topical PDRN is interesting, and the Korean aesthetic medicine data from injected protocols is genuinely compelling, but it does not automatically transfer to serum form. For people interested in peptide-based skin interventions with more clinical backing, the conversation shifts from cosmetic counters to prescription dermatology and, in some cases, regulated telehealth platforms where injectable formulations are evaluated individually. Buying a $40 ampoule because it contains the same ingredient class as a clinical treatment is a common and understandable leap. It is just not the same thing, and the evidence does not pretend it is.